Literature DB >> 26005537

Synthesis of mixed opioid affinity cyclic endomorphin-2 analogues with fluorinated phenylalanines.

Justyna Piekielna1, Renata Perlikowska1, Jean Claude do-Rego2, Jean-Luc do-Rego3, Maria Camilla Cerlesi4, Girolamo Calo4, Alicja Kluczyk5, Krzysztof Łapiński6, Csaba Tömböly7, Anna Janecka1.   

Abstract

As part of our continuing studies on the structure-activity relationships of cyclic pentapeptides based on the structure of endomorphin-2 (EM-2), we report here the synthesis and biological activities of a new series of analogues of a general sequence Tyr/Dmt-c[d-Lys-Phe-Phe-Asp]NH2 (where Dmt = 2',6'-dimethyltyrosine), incorporating fluorinated amino acids: 4-fluorophenylalanine (4-F-Phe), 2,4-difluorophenylalanine (2,4-F-Phe), or 4-trifluoromethylphenylalanine (4-CF3-Phe) instead of the Phe residue in position 3 or 4. Depending on the fluorinated amino acid residue and its position in the sequence, analogues were mixed, high affinity MOP/KOP receptor agonists, MOP/DOP/KOP agonists, or selective KOP agonists. The in vitro potencies and efficacies of all novel analogues were assessed in calcium mobilization assay. The most potent analogues, Dmt-c[d-Lys-Phe-4-F-Phe-Asp]NH2 and Dmt-c[d-Lys-Phe-2,4-F-Phe-Asp]NH2, were tested in vivo in the mouse hot-plate test. They produced strong antinociceptive effect not only after intracerebroventricular but also after intraperitoneal injection, indicating that they were able to cross the blood-brain barrier.

Entities:  

Keywords:  Opioid receptor affinity; antinociceptive activity; blood−brain barrier; calcium mobilization assay

Year:  2015        PMID: 26005537      PMCID: PMC4434475          DOI: 10.1021/acsmedchemlett.5b00056

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

Review 1.  The endomorphin system and its evolving neurophysiological role.

Authors:  Jakub Fichna; Anna Janecka; Jean Costentin; Jean-Claude Do Rego
Journal:  Pharmacol Rev       Date:  2007-03       Impact factor: 25.468

Review 2.  Bioavailability of endomorphins and the blood-brain barrier--a review.

Authors:  Renata Perlikowska; Anna Janecka
Journal:  Med Chem       Date:  2014       Impact factor: 2.745

3.  Synthesis and biological evaluation of cyclic endomorphin-2 analogs.

Authors:  Renata Perlikowska; Jean Claude do-Rego; Aurore Cravezic; Jakub Fichna; Anna Wyrebska; Geza Toth; Anna Janecka
Journal:  Peptides       Date:  2009-12-06       Impact factor: 3.750

4.  Synthesis and biological evaluation of an orally active glycosylated endomorphin-1.

Authors:  Pegah Varamini; Friederike M Mansfeld; Joanne T Blanchfield; Bruce D Wyse; Maree T Smith; Istvan Toth
Journal:  J Med Chem       Date:  2012-06-15       Impact factor: 7.446

Review 5.  Interactions between kappa opioid agonists and cocaine. Preclinical studies.

Authors:  N K Mello; S S Negus
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

6.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  cis-4-amino-L-proline residue as a scaffold for the synthesis of cyclic and linear endomorphin-2 analogues: part 2.

Authors:  Adriano Mollica; Francesco Pinnen; Azzurra Stefanucci; Luisa Mannina; Anatoly P Sobolev; Gino Lucente; Peg Davis; Josephine Lai; Shou-Wu Ma; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2012-09-25       Impact factor: 7.446

8.  Chimeric G proteins in fluorimetric calcium assays: experience with opioid receptors.

Authors:  Valeria Camarda; Girolamo Calo'
Journal:  Methods Mol Biol       Date:  2013

9.  Differential receptor binding characteristics of consecutive phenylalanines in micro-opioid specific peptide ligand endomorphin-2.

Authors:  Takeshi Honda; Naoto Shirasu; Kaname Isozaki; Michiaki Kawano; Daiki Shigehiro; Yoshiro Chuman; Tsugumi Fujita; Takeru Nose; Yasuyuki Shimohigashi
Journal:  Bioorg Med Chem       Date:  2007-03-12       Impact factor: 3.641

10.  Antinociceptive effect of D-Lys(2), Dab(4)N-(ureidoethyl)amide, a new cyclic 1-4 dermorphin/deltorphin analog.

Authors:  Bożena Antkowiak; Małgorzata Paluch; Magdalena Ciechanowska; Małgorzata Nawrocka; Krzysztof Bańkowski; Olga Michalak; Janusz Kocik; Marek Kowalczyk; Jan Izdebski
Journal:  Pharmacol Rep       Date:  2014-04-26       Impact factor: 3.024

View more
  4 in total

Review 1.  Cyclic Opioid Peptides.

Authors:  Michael Remesic; Yeon Sun Lee; Victor J Hruby
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

2.  Antinociceptive potency of a fluorinated cyclopeptide Dmt-c[D-Lys-Phe-p-CF3-Phe-Asp]NH2.

Authors:  Justyna Piekielna-Ciesielska; Adriano Mollica; Stefano Pieretti; Jakub Fichna; Agata Szymaszkiewicz; Marta Zielińska; Radzisław Kordek; Anna Janecka
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

3.  Synthesis, Pharmacological Evaluation, and Computational Studies of Cyclic Opioid Peptidomimetics Containing β3-Lysine.

Authors:  Karol Wtorek; Piotr F J Lipiński; Anna Adamska-Bartłomiejczyk; Justyna Piekielna-Ciesielska; Jarosław Sukiennik; Alicja Kluczyk; Anna Janecka
Journal:  Molecules       Date:  2021-12-28       Impact factor: 4.411

4.  Design, Synthesis and Functional Analysis of Cyclic Opioid Peptides with Dmt-Tic Pharmacophore.

Authors:  Arijit Sarkar; Anna Adamska-Bartlomiejczyk; Justyna Piekielna-Ciesielska; Karol Wtorek; Alicja Kluczyk; Attila Borics; Anna Janecka
Journal:  Molecules       Date:  2020-09-17       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.